VERAXA Biotech AG (NASDAQ: VRXA) has announced the appointment of Carl von Halem as interim chief financial officer, effective immediately, as the company navigates a leadership transition in its finance department. Von Halem succeeds Torsten Bürgermeister, who has stepped down from the role. The company stated that it is in the final stages of discussions with a permanent CFO candidate, who is expected to support VERAXA’s next phase of expansion and operational growth. An update on the appointment will be provided in due course.
Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA’s public listing. The company cited his extensive experience in corporate finance, life sciences, and technology-driven businesses, as well as his familiarity with VERAXA’s operations and strategic development, as key qualifications for leading the finance function during this transition period. His appointment is expected to ensure continuity and stability as the company continues to advance its pipeline of next-generation antibody-based therapeutics.
VERAXA is building a premier engine for the discovery and development of antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company is powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. Founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), VERAXA leverages world-renowned research to drive innovation in life sciences.
The appointment of von Halem comes at a critical time for VERAXA as it seeks to strengthen its financial leadership and position itself for future growth. Investors and stakeholders are closely watching the company’s progress, as detailed in the full press release available at https://nnw.fm/BjjY6. For the latest news and updates on VRXA, the company’s newsroom can be accessed at http://nnw.fm/VRXA.
VERAXA’s focus on innovative antibody formats, such as its BiTAC technology, underscores its commitment to addressing unmet medical needs in oncology and other therapeutic areas. The company’s ability to attract experienced executives like von Halem reflects confidence in its strategic direction and pipeline potential. As VERAXA continues to execute its development plans, the interim CFO’s leadership will be instrumental in maintaining financial discipline and supporting operational milestones.
